Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.53 |
| ▸ | NPC1 | O15118 | 14/20 | 0.53 |
| ▸ | GFER | P55789 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | TP53 | P04637 | 8/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26319866 | 0.86 | MAPT (0.53) | RAB9ANPC1MAPTKDM4ETP53 | |
| SCHEMBL23403728 | 0.82 | RAB9A (0.53) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL2242717 | 0.81 | RAB9A (0.49) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL10172908 | 0.80 | MAPT (0.58) | RAB9ANPC1MAPTKDM4ETP53 | |
| SCHEMBL10223594 | 0.80 | RAB9A (0.54) | RAB9ANPC1MAPTKDM4ETP53 | |
| SCHEMBL28036595 | 0.79 | RAB9A (0.47) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL2609446 | 0.79 | LMNA (0.56) | RAB9ANPC1MAPTKDM4ETP53 | |
| SCHEMBL20966351 | 0.79 | CHRNB2 (0.43) | RAB9ANPC1MAPTKDM4ETP53 | |
| Bromide SCHEMBL9224448 | 0.79 | RAB9A (0.53) | RAB9ANPC1MAPTKDM4ETP53 | |
| SCHEMBL4790659 | 0.79 | RAB9A (0.54) | RAB9ANPC1MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269721-B | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| EP-3983389-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114269721-A | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020249957-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | Enterprise Therapeutics Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | RAB9A 1430/4885NPC1 1106/4885GFER 4593/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | RAB9A 2719/4885NPC1 3021/4885GFER 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.